RTOG News

Minimize
25

 In a new phase III trial report from the National Clinical Trial Network group, NRG Oncology, recurrence-free and overall survival rates for women with stage I-II high-risk endometrial cancer were not superior following vaginal cuff brachytherapy plus chemotherapy when compared with pelvic radiation therapy. Risks of pelvic and para-aortic nodal recurrence and frequency of short-term side effects were greater for the brachytherapy-chemotherapy approach. High completion rates for each treatment arm suggest that both therapies are well-tolerated by patients. Findings will be presented today at the 59th Annual Meeting of the American Society for Radiation Oncology (ASTRO). Read the full press release here